Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.36 |
| ▸ | BBOX1 | O75936 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.35 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL2940736 | 0.87 | BBOX1 (0.37) | GPR3BBOX1KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL28569605 | 0.85 | BBOX1 (0.45) | GPR3BBOX1KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL28457960 | 0.83 | BBOX1 (0.37) | GPR3BBOX1KCNH2 | |
| Tetrylammonium SCHEMBL159930 | 0.82 | TSHR (0.42) | GPR3BBOX1KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL6895412 | 0.81 | KCNH2 (0.37) | GPR3BBOX1KCNH2ACHE | |
| Sulfuric Acid SCHEMBL7641807 | 0.81 | BBOX1 (0.42) | BBOX1 | |
| Trifluoromethanesulfonic Acid SCHEMBL216802 | 0.81 | GPR3 (0.38) | GPR3BBOX1KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL1171508 | 0.80 | ACHE (0.33) | BBOX1ACHE | |
| Trifluoromethanesulfonamide SCHEMBL28043545 | 0.80 | CA1 (0.55) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL1861472 | 0.80 | ALDH1A1 (0.33) | BBOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2973631-A2 | METHODS OF ENHANCING ELECTROCHEMICAL DOUBLE LAYER CAPACITOR (EDLC) PERFORMANCE AND EDLC DEVICES FORMED THEREFROM | Esionic Corp. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014144845-A2 | METHODS OF ENHANCING ELECTROCHEMICAL DOUBLE LAYER CAPACITOR (EDLC) PERFORMANCE AND EDLC DEVICES FORMED THEREFROM | ESIONIC ES, INC. (US) | 2014-09-18 | — | — | WO | claimed |
| US-20100046142-A1 | Electrolyte | ENERGY STORAGE SYSTEMS PTY LTD (AU) | 2010-02-25 | — | — | US | claimed |
| EP-2005504-A1 | ELECTROLYTE | CAP-XX Limited (AU) | 2008-12-24 | — | — | EP | claimed |
| WO-2007101303-A1 | ELECTROLYTE | CAP-XX LIMITED (AU) | 2007-09-13 | — | — | WO | claimed |
| US-20040222401-A1 | Electrochemically stable onium salts and electrolytes containing such for electrochemical capacitors | XU KANG (US) | 2004-11-11 | — | — | US | claimed |
| CN-119214318-A | Composition for preventing and treating complications of kidney disease dialysis patients, and preparation method, preparation and application thereof | 江西健乐医疗科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| EP-2973631-A2 | METHODS OF ENHANCING ELECTROCHEMICAL DOUBLE LAYER CAPACITOR (EDLC) PERFORMANCE AND EDLC DEVICES FORMED THEREFROM | Esionic Corp. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150263543-A1 | Methods Of Enhancing Electrochemical Double Layer Capacitor (EDLC) Performance And EDLC Devices Formed Therefrom | ESIONIC CORP (US) | 2015-09-17 | — | — | US | disclosed |
| WO-2014144845-A2 | METHODS OF ENHANCING ELECTROCHEMICAL DOUBLE LAYER CAPACITOR (EDLC) PERFORMANCE AND EDLC DEVICES FORMED THEREFROM | ESIONIC ES, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8475676-B2 | Electrolyte | CAP-XX LIMITED (AU) | 2013-07-02 | — | — | US | disclosed |
| US-20100046142-A1 | Electrolyte | ENERGY STORAGE SYSTEMS PTY LTD (AU) | 2010-02-25 | — | — | US | disclosed |
| US-20040222401-A1 | Electrochemically stable onium salts and electrolytes containing such for electrochemical capacitors | XU KANG (US) | 2004-11-11 | — | — | US | disclosed |
| US-6743947-B1 | HAVING ASYMMETRIC SUBSTITUTION ON CATION; ALTERING MELTING POINT AND SOLUBILITY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040222401-A1 | Electrochemically stable onium salts and electrolytes containing such for electrochemical capacitors | VDAC2, VDAC1, HCN2 | GPR3 4228/4885BBOX1 1644/4885KCNH2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.